Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
KRRO Financials Korro Bio, Inc.
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $6M | -$117M | 0.0% | -1906.4% | -$79M | — | $22M |
| 2024 | $2M | -$84M | 0.0% | -4047.1% | -$78M | — | $56M |
| 2023 | $0 | -$81M | — | — | -$75M | — | $166M |
| 2022 | — | -$58M | — | — | -$59M | — | $36M |
| 2021 | — | -$85M | — | — | -$79M | — | $80M |
| 2020 | — | -$27M | — | — | -$52M | — | $220M |
| 2019 | — | -$19M | — | — | $33M | $180000 | $200M |
| 2018 | — | -$19M | — | — | -$17M | $349000 | $42M |
| 2017 | — | -$20M | — | — | -$16M | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$20M | — | — | -$16M | — | $62M |
| Dec '25 | $1M | -$50M | 0.0% | -3900.6% | -$18M | — | $22M |
| Sep '25 | $1M | -$18M | 0.0% | -1764.9% | -$17M | — | $24M |
| Jun '25 | $1M | -$26M | 0.0% | -1863.2% | -$19M | — | $34M |
| Mar '25 | $3M | -$23M | 0.0% | -981.2% | -$25M | — | $64M |
| Dec '24 | $2M | -$21M | 0.0% | -1014.5% | -$9M | — | $56M |
| Sep '24 | $0 | -$21M | — | — | -$21M | — | $63M |
| Jun '24 | $0 | -$22M | — | — | -$21M | — | $91M |
| Mar '24 | $0 | -$20M | — | — | -$28M | — | $139M |
| Dec '23 | — | -$25M | — | — | -$23M | — | $166M |
| Sep '23 | — | -$18M | — | — | -$12M | — | $42M |
| Jun '23 | — | -$18M | — | — | -$19M | — | $40M |
| Mar '23 | — | -$20M | — | — | -$21M | — | $41M |
| Dec '22 | — | $6M | — | — | -$16M | — | $36M |
| Sep '22 | — | -$20M | — | — | -$12M | — | $44M |
| Jun '22 | — | -$21M | — | — | -$13M | — | $42M |
| Mar '22 | — | -$23M | — | — | -$17M | — | $50M |
| Dec '21 | — | -$22M | — | — | -$18M | — | $80M |
| Sep '21 | — | -$25M | — | — | -$15M | — | $112M |
| Jun '21 | — | -$18M | — | — | -$20M | — | $135M |
Valuation over time
How the market has priced KRRO against its own fundamentals since 2023-11 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 240.5× (Dec '24) to 27.1× (Jun '26).
P/S
Frequently asked questions
Is KRRO growing its revenue and profit?
See the revenue and net-income charts above for Korro Bio, Inc.'s multi-year trend.
How much debt does KRRO have?
As of FY2025, Korro Bio, Inc. reported — of total debt against $22M of cash.
What is KRRO's profit margin?
In FY2025, gross margin was —, operating margin -1906.4%, and net margin -1834.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.